Pramipexole-Induced Reversible Heart Failure

被引：8

作者：

Apraxine, Matve I. ^{[1
]}

Pasquet, Agnes ^{[2
,3
]}

Jeanjean, Anne ^{[4
,5
]}

机构：

[1] UCL, Clin Univ St Luc, Brussels, Belgium

[2] Catholic Univ Louvain, Inst Rech Expt & Clin, Pole Rech Cardiovasc, Brussels, Belgium

[3] Clin Univ St Luc, Div Cardiol, Brussels, Belgium

[4] Catholic Univ Louvain, Inst Neurosci IoNS, Brussels, Belgium

[5] Clin Univ St Luc, Dept Neurol, Ave Hippocrate 10, B-1200 Brussels, Belgium

来源：

MOVEMENT DISORDERS CLINICAL PRACTICE | 2014年 / 1卷 / 04期

关键词：

pramipexole; heart failure; Parkinson;

D O I：

10.1002/mdc3.12096

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：381 / 382

页数：2

共 8 条

[1] Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease [J].

Antonini, Angelo ;

Poewe, Werner .

LANCET NEUROLOGY, 2007, 6 (09) :826-829

[2] Sustained Administration of Pramipexole Modifies the Spontaneous Firing of Dopamine, Norepinephrine, and Serotonin Neurons in the Rat Brain [J].

Chernoloz, O. ;

El Mansari, M. ;

Blier, P. .

NEUROPSYCHOPHARMACOLOGY, 2009, 34 (03) :651-661

[3] Risk of Heart Failure Associated with Dopamine Agonists: A Nested Case-Control Study [J].

Hsieh, P. H. ;

Hsiao, F. Y. .

DRUGS & AGING, 2013, 30 (09) :739-745

[4] ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC [J].

McMurray, John J. V. ;

Adamopoulos, Stamatis ;

Anker, Stefan D. ;

Auricchio, Angelo ;

Boehm, Michael ;

Dickstein, Kenneth ;

Falk, Volkmar ;

Filippatos, Gerasimos ;

Fonseca, Candida ;

Angel Gomez-Sanchez, Miguel ;

Jaarsma, Tiny ;

Kober, Lars ;

Lip, Gregory Y. H. ;

Maggioni, Aldo Pietro ;

Parkhomenko, Alexander ;

Pieske, Burkert M. ;

Popescu, Bogdan A. ;

Ronnevik, Per K. ;

Rutten, Frans H. ;

Schwitter, Juerg ;

Seferovic, Petar ;

Stepinska, Janina ;

Trindade, Pedro T. ;

Voors, Adriaan A. ;

Zannad, Faiez ;

Zeiher, Andreas ;

Bax, Jeroen J. ;

Baumgartner, Helmut ;

Ceconi, Claudio ;

Dean, Veronica ;

Deaton, Christi ;

Fagard, Robert ;

Funck-Brentano, Christian ;

Hasdai, David ;

Hoes, Arno ;

Kirchhof, Paulus ;

Knuuti, Juhani ;

Kolh, Philippe ;

McDonagh, Theresa ;

Moulin, Cyril ;

Popescu, Bogdan A. ;

Reiner, Zeljko ;

Sechtem, Udo ;

Sirnes, Per Anton ;

Tendera, Michal ;

Torbicki, Adam ;

Vahanian, Alec ;

Windecker, Stephan ;

McDonagh, Theresa ;

Sechtem, Udo .

EUROPEAN HEART JOURNAL, 2012, 33 (14) :1787-1847

[5] The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease [J].

Mokhles, M. Mostafa ;

Trifiro, Gianluca ;

Dieleman, Jeanne P. ;

Haag, Mendel D. ;

van Soest, Eva M. ;

Verhamme, Katia M. C. ;

Mazzaglia, Giampiero ;

Herings, Ron ;

de Luise, Cynthia ;

Ross, Douglas ;

Brusselle, Guy ;

Colao, Annamaria ;

Haverkamp, Willem ;

Schade, Rene ;

van Camp, Guy ;

Zanettini, Renzo ;

Sturkenboom, Miriam C. J. M. .

PHARMACOLOGICAL RESEARCH, 2012, 65 (03) :358-364

[6] Inhibition of dopamine neuron firing by pramipexole, a dopamine D-3 receptor-preferring agonist, comparison to other dopamine receptor agonists [J].

Piercey, MF ;

Hoffmann, WE ;

Smith, MW ;

Hyslop, DK .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 312 (01) :35-44

[7] Dopamine agonist use and the risk of heart failure [J].

Renoux, Christel ;

Dell'Aniello, Sophie ;

Brophy, James M. ;

Suissa, Samy .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 (01) :34-41

[8]

United States Food and Drug Administration (FDA), FDA DRUG SAF COMM ON

← 1 →